查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1873992

生物防禦市場

Biodefense Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024年，生物防禦市場規模約為147.7億美元，預計到2031年將成長至216.2億美元，2031年至2032年的年複合成長率（CAGR）為6.1%。巨量資料和人工智慧的融合為開展各種生物威脅的技術評估提供了重要機遇，並為追蹤疾病爆發提供了絕佳機會。因此，預測分析可望變革生物防禦領域，成為該市場的關鍵趨勢。

生物防禦市場分析

基因工程和生物技術的最新進展使得改造致命病毒和自然存在的病毒變得更加容易，這可能加劇病毒的危害。人們對生物攻擊和疫情爆發的災難性後果的認知不斷提高，導致對生物防禦解決方案的需求激增。世界各國政府都在大力投資生物防禦能力建設，這推動了市場成長。技術進步和對研發的日益重視促成了先進創新型生物防禦解決方案的問世。合成生物學、基因組學和資料分析等技術創新推動了這些解決方案的開發，增強了識別、表徵和緩解生物威脅的能力。此外，政府、國防部門和商業實體之間的合作促進了綜合生物防禦戰略的製定，進一步推動了市場成長。

生物防禦市場概覽

生物防禦涵蓋一系列旨在保護國家免受生物威脅或傳染病侵害的活動和技術。它應對與流行病、生物恐怖主義和其他生物突發事件相關的風險。在美國，聯邦政府協調各項計畫並分配預算，以預防、應對和管理生物災害。美國的生物防禦計劃，即國家生物防禦戰略，涉及各級政府與私營機構和其他利益相關者的合作，共同進行生物防禦活動。此外，加拿大國家傳染病合作中心透過網路研討會、播客、線上資源和出版物，向政策制定者、公共衛生官員、衛生檢查員和其他人員提供有關新興傳染病的最新資訊。因此，旨在加強生物防禦體系的政府措施預計將在預測期內推動市場成長。

戰略洞察

生物防禦市場促進因素與機遇

政府扶持措施推動市場成長

已開發國家政府正在實施各種措施和預防策略來應對生物恐怖主義威脅。在聯邦政府投入增加、技術進步和公眾意識提高的推動下，各國儲備了疫苗和生物威脅檢測工具，以保障公眾健康。主要行業參與者的存在也對市場產生了積極影響。 2018年，美國政府推出了《國家生物防禦戰略及實施計畫》，以及《國家安全戰略》、《國家國防戰略》、《國家反恐戰略》和《國家反大規模殺傷性武器戰略》，所有這些戰略都強調了生物安全和生物防禦的重要性。

在印度等新興市場，國防研究與發展組織等機構正在研發應對生物攻擊的對策，並大力加強軍隊應對此類威脅的準備。過去二十年來，全球對生物恐怖主義的認知日益提高，同時，旨在應對這些威脅的各種提案和會議也層出不窮，這極大地推動了對生物防禦的需求。全球政府的各項措施為生物防禦領域的企業創造了機遇，從而促進了市場成長。

技術應用普及將促進市場成長

包括用於法醫病原體檢測的基因晶片、資料庫管理系統、生物防禦藥物研發中的先進檢測硬體以及奈米技術在內的多種技術的日益普及，正在增強生物防禦能力。許多此類技術被單獨或組合使用，以創建和開發各種生物防禦工具。目前，基因工程是生物防禦中最關鍵的技術，它涉及對遺傳物質的人工操作和轉移。此外，基因療法有望用於治療多種疾病。許多專家預測，未來的生物武器可能是客製化生物武器，而這項技術可能在發現許多目前未知疾病的治療方法方面發揮關鍵作用。分子生物學和基因工程的最新進展催生了疫苗研發的新策略，這很可能在未來為生物防禦市場創造巨大的成長機會。

生物防禦市場報告細分分析

生物防禦市場分析按產品類型細分。

  • 市場依疾病類別分為炭疽、天花、肉毒桿菌中毒、輻射/核輻射等。 2023年，炭疽病細分市場佔據最大市場佔有率，預計在預測期內將保持最高的複合年成長率。

按地域分類的生物防禦市場佔有率分析

生物防禦市場報告的地理分析分為五個區域：北美、亞太、歐洲、中東和非洲以及南美和中美洲。

北美一直是生物防禦市場的領先地區。對人類、動物和環境的生物威脅是美國及其國民面臨的最緊迫挑戰之一。隨著這些生物威脅的不斷升級，美國正優先提升自身能力，並將應對生物威脅和生物恐怖主義的準備工作視為國家安全的關鍵組成部分。該地區對國家安全的高度重視、完善的醫療保健體係以及強大的研發能力，都促進了市場成長。由於政府的積極舉措、與行業參與者的合作以及對生物恐怖主義威脅的高度防範，該地區已在生物防禦技術（包括治療方法、疫苗和檢測系統）方面進行了大量投資。

由生物醫學高級研究與發展局（BARDA）、國家過敏和傳染病研究所（NIAID）、疾病管制與預防中心（CDC）、美國衛生與公眾服務部（ASPR）和美國食品藥物管理局（FDA）等機構實施的生物防禦策略也促進了該地區的成長。美國軍方和民事機構對生物防禦的大量投入是推動該地區收入佔有率領先的另一個關鍵因素。

預計未來幾年亞太地區將實現最高的複合年成長率，這主要得益於研發投入的增加、生物防禦的重要性以及可能導致突發事件的危險生物材料威脅的日益加劇。該地區易受傳染病侵襲，人口眾多，加上其擁有先進的醫療基礎設施，因此對生物防禦產品和技術的需求不斷成長。

生物防禦市場報告範圍

生物防禦市場新聞及最新進展

生物防禦市場評估是基於從一手和二手研究中收集的定性和定量資料，包括重要的企業出版物、協會資料和資料庫。以下是生物防禦市場的一些最新發展和策略：

  • 2022年2月，Appili Therapeutics公司宣布，已從美國國防部透過國防威脅降低局聯合科學技術辦公室獲得超過1000萬美元的資金，用於推進其生物防禦候選疫苗ATI-1701的研發。該疫苗旨在預防土拉弗朗西斯菌感染。預計這筆資金將增強該公司在生物防禦市場的佔有率並促進其業務成長。 （資料來源：Appili Therapeutics，新聞稿，2022）
  • 2022年9月，Emergent BioSolutions Inc.與Chimerix, Inc.最終達成協議，取得TEMBEXA（brincidofovir）的全球獨家經銷權。 TEMBEXA是第一個獲得美國FDA核准用於治療所有年齡層天花患者的口服抗病毒藥物。 （資料來源：Emergent BioSolutions Inc.，新聞稿，2022年）
  • 2023年7月，Emergent BioSolutions公司生產的CYFENDUS（炭疽疫苗吸附佐劑，原名AV7909）獲得美國FDA批准，用於18至65歲人群在疑似或確診接觸炭疽桿菌後進行暴露後預防，需與推薦的抗菌藥物聯合使用。 （資料來源：Emergent BioSolutions公司，新聞稿，2023年）

生物防禦市場報告涵蓋範圍和成果

這份題為《生物防禦市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 涵蓋範圍內所有關鍵細分市場的全球、區域和國家層面的市場規模和預測
  • 市場動態，例如促進因素、限制因素和關鍵機會
  • 未來主要趨勢
  • 詳細的PEST/波特五力模型與SWOT分析
  • 全球及區域市場分析，涵蓋關鍵市場趨勢、主要參與者、法規及最新發展動態
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者和最新發展動態
  • 公司詳細概況

目錄

第1章：引言

第2章：生物防禦市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：生物防禦與市場格局

  • 概述
  • PEST分析
    • 北美洲
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美洲和中美洲
  • 專家意見

第5章：全球生物防禦市場及產業動態

  • 關鍵促進因素
    • 有利的政府舉措
    • 自然發生的疫情數量增加
    • 生物武器和核子洲際彈道飛彈的威脅日益加劇。
  • 主要市場限制因素
    • 發展中經濟體及低度開發經濟體政府研發投入不足
  • 主要市場機遇
    • 技術應用日益普及
  • 未來趨勢
    • 預測分析將重塑生物防禦市場
  • 影響分析

第6章：生物防禦市場及全球分析

  • 全球生物防禦市場收入預測與分析
  • 全球生物防禦市場（依地域分類）－預測與分析
  • 關鍵參與者的市場定位

第7章：生物防禦市場分析及產品分類

  • 概述
  • 生物防禦市場收入佔有率（按產品分類）（2024 年和 2031 年）
  • 炭疽病
  • 天花
  • 肉毒桿菌中毒
  • 輻射/核能
  • 其他

第8章：生物防禦市場及地理分析

    • 概述
    • 北美：生物防禦市場、收入及至2031年預測
    • 北美：生物防禦市場（按產品分類），2024 年和 2031 年
    • 北美：生物防禦市場（按國家分類），2024 年和 2031 年（%）
    • 美國：生物防禦市場、收入及至2031年預測
      • 美國：生物防禦市場、收入及至2031年預測
      • 美國：生物防禦市場（按產品類型分類），2024 年和 2031 年
    • 加拿大：生物防禦市場、收入及至2031年預測
      • 加拿大：生物防禦市場、收入及至2031年預測
      • 加拿大：生物防禦市場（按產品類型分類），2024 年和 2031 年
    • 墨西哥：生物防禦市場、收入及至2031年預測
      • 墨西哥：生物防禦市場、收入及至2031年預測
      • 墨西哥：生物防禦市場（按產品類型分類），2024 年和 2031 年
  • 歐洲：生物防禦市場
    • 概述
    • 歐洲：生物防禦市場－收入及至2031年的預測
    • 歐洲：生物防禦市場（依產品分類），2024 年和 2031 年
    • 歐洲：生物防禦市場（按國家分類），2018 年和 2031 年（%）
    • 德國：生物防禦市場、收入及至2031年的預測
      • 德國：生物防禦市場、收入及至2031年的預測
      • 德國：生物防禦市場（依產品類型分類），2024 年和 2031 年
    • 英國：生物防禦市場、收入及至2031年預測
      • 英國：生物防禦市場、收入及至2031年預測
      • 英國：生物防禦市場（依產品類型分類），2024 年和 2031 年
    • 法國：生物防禦市場、收入及至2031年預測
      • 法國：生物防禦市場、收入及至2031年預測
      • 法國：生物防禦市場（依產品類型分類），2024 年和 2031 年
    • 西班牙：生物防禦市場、收入及至2031年預測
      • 西班牙：生物防禦市場、收入及至2031年預測
      • 西班牙：生物防禦市場（按產品類型分類），2024 年和 2031 年
    • 義大利：生物防禦市場、收入及至2031年預測
      • 義大利：生物防禦市場、收入及至2031年預測
      • 義大利：生物防禦市場（依產品類型分類），2024 年和 2031 年
  • 亞太地區：生物防禦市場
    • 概述
    • 亞太地區：生物防禦市場－收入及至2031年預測
    • 亞太地區：生物防禦市場（按產品分類），2024 年和 2031 年
    • 亞太地區：生物防禦市場（按國家/地區分類），2018 年和 2031 年（%）
    • 中國：生物防禦市場、收入及至2031年預測
      • 中國：生物防禦市場、收入及至2031年預測
      • 中國：生物防禦市場（依產品類型分類），2024 年和 2031 年
    • 日本：生物防禦市場、收入及至2031年預測
      • 日本：生物防禦市場、收入及至2031年預測
      • 日本：生物防禦市場（依產品類型分類），2024 年和 2031 年
    • 印度：生物防禦市場、收入及至2031年預測
      • 印度：生物防禦市場、收入及至2031年預測
      • 印度：生物防禦市場（按產品類型分類），2024 年和 2031 年
    • 韓國：生物防禦市場、收入及至2031年預測
      • 韓國：生物防禦市場、收入及至2031年預測
      • 韓國：生物防禦市場（按產品類型分類），2024 年和 2031 年
    • 澳洲：生物防禦市場、收入及至2031年的預測
      • 澳洲：生物防禦市場、收入及至2031年預測
      • 澳洲：生物防禦市場（依產品類型分類），2024 年和 2031 年
  • 南美洲和中美洲：生物防禦市場
    • 概述
    • 南美洲和中美洲：生物防禦市場－收入及至2031年的預測
    • 南美洲和中美洲：生物防禦市場（按產品分類），2024 年和 2031 年
    • 南美洲和中美洲：生物防禦市場（按國家分類），2018 年和 2031 年（%）
    • 巴西：生物防禦市場、收入及至2031年預測
      • 巴西：生物防禦市場、收入及至2031年預測
      • 巴西：生物防禦市場（依產品類型分類），2024 年和 2031 年
    • 阿根廷：生物防禦市場、收入及至2031年預測
      • 阿根廷：生物防禦市場、收入及至2031年預測
      • 阿根廷：生物防禦市場（按產品類型分類），2024 年和 2031 年

第9章：新冠肺炎疫情對全球生物防禦市場的影響

  • 北美洲
  • 歐洲
  • 亞太
  • MEA
  • 薩姆

第10章：生物防禦市場及產業概況

  • 概述
  • 2016-2020年生物防禦市場成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第11章：公司簡介

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • pluristem

第12章：附錄

簡介目錄
Product Code: TIPRE00005377

In 2024, the biodefense market was valued at approximately US$ 14.77 billion and is anticipated to grow to US$ 21.62 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.1% from 2031 to 2031. The integration of big data and artificial intelligence presents significant opportunities for conducting technical evaluations of various biothreats and offers an exceptional chance to track disease outbreaks. Consequently, predictive analytics is poised to transform the biodefense sector, emerging as a pivotal trend in the market.

Biodefense Market Analysis

Recent advancements in genetic engineering and biotechnology have made it easier to modify lethal and naturally occurring viruses, potentially increasing their harmful effects. The growing awareness of the catastrophic consequences of biological attacks and outbreaks has led to a heightened demand for biodefense solutions. Governments worldwide are investing heavily in biodefense capabilities, which is driving market growth. Technological advancements and a stronger focus on research and development have resulted in the introduction of advanced and innovative biodefense solutions. The development of these solutions is fueled by technological innovations such as synthetic biology, genomics, and data analytics, which enhance the ability to identify, characterize, and mitigate biological threats. Furthermore, collaborations among government, defense, and commercial entities have facilitated the creation of comprehensive biodefense strategies, further propelling market growth.

Biodefense Market Overview

Biodefense encompasses a variety of activities and technologies aimed at safeguarding a nation from biological threats or infectious diseases. It addresses the risks associated with pandemics, bioterrorism, and other biological emergencies. In the United States, the federal government coordinates programs and allocates budgets to prevent, respond to, and manage biological disasters. The US biological defense program, known as the National Biodefense Strategy, involves collaborative efforts across various government levels in partnership with private organizations and other stakeholders to conduct biodefense activities. Additionally, Canada's National Collaborating Centre for Infectious Diseases provides up-to-date information on emerging infectious diseases to policymakers, public health officials, health inspectors, and others through webinars, podcasts, online resources, and publications. Therefore, government initiatives aimed at enhancing the biodefense system are expected to support market growth during the forecast period.

Strategic Insights

Biodefense Market Drivers and Opportunities

Supportive Government Initiatives to Propel Market Growth

Governments in developed countries are implementing various measures and preventive strategies to counter bioterrorism threats. They maintain stockpiles of vaccines and bio-threat detection tools to safeguard public health, driven by increased federal funding, technological advancements, and heightened public awareness. The presence of major industry players also positively impacts the market. In 2018, the US government introduced the National Biodefense Strategy and Implementation Plan, along with the National Security Strategy, National Defense Strategy, National Counterterrorism Strategy, and National Counter WMD Strategy, all emphasizing biosecurity and biodefense.

In emerging markets like India, organizations such as the Defense Research and Development Organization are developing countermeasures against biological attacks, with significant efforts to prepare military forces for such threats. Over the past two decades, there has been a growing focus on raising awareness about bioterrorism globally, alongside various proposals and meetings aimed at combating these threats, which significantly drives the demand for biodefense. Global government initiatives create opportunities for companies in the biodefense sector, thereby fostering market growth.

Increased Technology Adoption to Boost Market Growth

The rising adoption of technologies, including gene chips for pathogen detection in forensic applications, database management systems, advanced detection hardware in biodefense drug development, and nanotechnology, is enhancing biological defense capabilities. Many of these technologies are utilized independently or in combination to create and develop various biodefense tools. Currently, genetic engineering is the most critical technology for biodefense, involving the artificial manipulation and transfer of genetic material. Additionally, gene therapy holds promise for treating various diseases. Many experts predict that future bioweapons may be designer bioweapons, and this technology could play a crucial role in discovering cures for many currently unknown diseases. Recent advancements in molecular biology and genetic engineering have led to new strategies for vaccine development, likely creating substantial growth opportunities for the biodefense market in the future.

Biodefense Market Report Segmentation Analysis

The biodefense market analysis is segmented by product.

  • The market is categorized into anthrax, smallpox, botulism, radiation/nuclear, and others. The anthrax segment accounted for the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period.

Biodefense Market Share Analysis by Geography

The geographic analysis of the biodefense market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has been the leading region in the biodefense market. The biological threats to humans, animals, and the environment are among the most pressing challenges faced by the US and its national community. As these biological threats continue to escalate, the US is prioritizing the enhancement of its capabilities and considers preparedness for biothreats and bioterrorism as a critical aspect of national security. The region's strong focus on national security, well-established healthcare systems, and robust research and development capabilities contribute to market growth. Due to proactive government initiatives, collaborations with industry players, and a high level of preparedness against bioterrorism threats, significant investments in biodefense technologies, including therapeutics, vaccines, and detection systems, have been made in this region.

Biodefense strategies implemented by organizations such as BARDA, NIAID, CDC, ASPR, and the FDA are also contributing to the region's growth. Substantial funding from US military and civilian agencies for biodefense is another key factor driving the region's leading revenue share.

Asia Pacific is projected to experience the highest CAGR in the coming years, supported by increasing R&D investments, the importance of biodefense, and the rising threat of hazardous biological materials that can lead to emergencies. The region's vulnerability to infectious diseases and its large population have heightened the demand for biodefense products and technologies, along with the presence of advanced healthcare infrastructure.

Biodefense Market Report Scope

Biodefense Market News and Recent Developments

The biodefense market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the biodefense market:

  • In February 2022, Appili Therapeutics Inc. announced it received over US$ 10 million in funding from the US Department of Defense, through the Joint Science and Technology Office of the Defense Threat Reduction Agency, to advance its biodefense vaccine candidate, ATI-1701, which aims to prevent infection with Francisella tularensis. This funding is expected to enhance the company's presence and growth in the biodefense market. (Source: Appili Therapeutics, Press Release, 2022)
  • In September 2022, Emergent BioSolutions Inc. finalized its agreement with Chimerix, Inc. to acquire exclusive global rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the US FDA for treating smallpox across all age groups. (Source: Emergent BioSolutions Inc., News Release, 2022)
  • In July 2023, Emergent BioSolutions Inc. received US FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis against disease following suspected or confirmed exposure to Bacillus anthracis in individuals aged 18 to 65, when administered alongside recommended antibacterial drugs. (Source: Emergent BioSolutions Inc., News Release, 2023)

Biodefense Market Report Coverage and Deliverables

The report titled "Biodefense Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis covering key market trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • Detailed company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Biodefense Market and By Product
    • 1.3.2 Global Biodefense Market and By Geography

2. Biodefense Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Biodefense and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
    • 4.2.4 Middle East and Africa
    • 4.2.5 South and Central America
  • 4.3 Expert Opinion

5. Global Biodefense Market and Industry Dynamics

  • 5.1 Key Drivers
    • 5.1.1 Presence of Favourable Government Initiatives
    • 5.1.2 Increase in the Number of Naturally Occurring Outbreaks
    • 5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM
  • 5.2 Key Market Restraints
    • 5.2.1 Low R and D Funding by Government in Developing and Underdeveloped Economies
  • 5.3 Key Market Opportunities
    • 5.3.1 Increased Adoption of Technologies
  • 5.4 Future Trends
    • 5.4.1 Predictive Analytics to Reshape Biodefense Market
  • 5.5 Impact Analysis

6. Biodefense Market and Global Analysis

  • 6.1 Global Biodefense Market Revenue Forecast And Analysis
  • 6.2 Global Biodefense Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Biodefense Market Analysis and By Product

  • 7.1 Overview
  • 7.2 Biodefense Market Revenue Share, by Product (2024 and 2031)
  • 7.1 Anthrax
    • 7.1.1 Overview
    • 7.1.2 Anthrax: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Small pox
    • 7.2.1 Overview
    • 7.2.2 Small pox: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Botulism
    • 7.3.1 Overview
    • 7.3.2 Botulism: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Radiation/Nuclear
    • 7.4.1 Overview
    • 7.4.2 Radiation/Nuclear: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)

8. Biodefense Market and Geographic Analysis

    • 8.1.1 Overview
    • 8.1.2 North America: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
    • 8.1.3 North America: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.1.4 North America: Biodefense Market, by Country, 2024 and 2031 (%)
    • 8.1.5 US: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.5.1 US: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.5.2 US: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.1.6 Canada: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.6.1 Canada: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.6.2 Canada: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.1.7 Mexico: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.7.1 Mexico: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.7.2 Mexico: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
  • 8.2 Europe: Biodefense Market
    • 8.2.1 Overview
    • 8.2.2 Europe: Biodefense Market - Revenue and Forecast to 2031 (USD Million)
    • 8.2.3 Europe: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.2.4 Europe: Biodefense Market, by Country, 2018 and 2031 (%)
    • 8.2.5 Germany: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.5.1 Germany: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.5.2 Germany: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.6 UK: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.6.1 UK: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.6.2 UK: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.7 France: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.7.1 France: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.7.2 France: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.8 Spain: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.8.1 Spain: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.8.2 Spain: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.9 Italy: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.9.1 Italy: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.9.2 Italy: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
  • 8.3 Asia Pacific: Biodefense Market
    • 8.3.1 Overview
    • 8.3.2 Asia Pacific: Biodefense Market - Revenue and Forecast to 2031 (USD Million)
    • 8.3.3 Asia Pacific: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.3.4 Asia Pacific: Biodefense Market, by Country, 2018 and 2031 (%)
    • 8.3.5 China: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.5.1 China: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.5.2 China: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.6 Japan: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.6.1 Japan: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.6.2 Japan: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.7 India: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.7.1 India: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.7.2 India: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.8 South Korea: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.8.1 South Korea: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.8.2 South Korea: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.9 Australia: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.9.1 Australia: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.9.2 Australia: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
  • 8.4 South and Central America: Biodefense Market
    • 8.4.1 Overview
    • 8.4.2 South and Central America: Biodefense Market - Revenue and Forecast to 2031 (US$ Million)
    • 8.4.3 South and Central America: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.4.4 South and Central America: Biodefense Market, by Country, 2018 and 2031 (%)
    • 8.4.5 Brazil: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.5.1 Brazil: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.5.2 Brazil: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.4.6 Argentina: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.6.1 Argentina: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.6.2 Argentina: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)

9. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BIODEFENSE MARKET

  • 9.1 North America: Impact assessment of COVID-19 Pandemic
  • 9.2 Europe: Impact assessment of COVID-19 Pandemic
  • 9.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic
  • 9.4 MEA: Impact assessment of COVID-19 Pandemic
  • 9.5 SAM: Impact assessment of COVID-19 Pandemic

10. Biodefence Market andIndustry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in The Biodefence Market, 2016-2020
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. COMPANY PROFILES

  • 11.1 Bavarian Nordic
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Alnylam Pharmaceuticals, Inc.
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 SIGA Technologies
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Emergent BioSolutions Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Cleveland Bio Labs
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Dynavax Technologies
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Elusys Therapeutics, Inc.
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Soligenix
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Altimmune
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 pluristem
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms